Asia-Pacific region sees boom in Biotech investment

7 March 2014

The Asia-Pacific (APAC) region is experiencing a significant boom in the volume of private equity (PE) and venture capital (VC) investments in biotechnology, with investors looking to cash in on the remarkable potential of the region’s health care sector, says an analyst with research and consulting firm GlobalData.

Adefemi Adenuga, GlobalData’s senior analyst covering Industry Dynamics, says that the APAC countries are being targeted by large pharmaceutical companies seeking to recover their loss of market exclusivity in Western Europe and the USA, due to patent expirations and slow growth.

In fact, GlobalData states that the volume of health care PE investment in the APAC region increased massively between 2011 and 2013, growing by 125.8% during that period. On the other hand, deal activities in Europe and North America decreased by 30.5% and 2.5% between 2012 and 2013, respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >